Thirty patients thyroidectomized for differentiated thyroid cancer were studied. Serum TSH was assayed in basal conditions and after TRH stimulation, while patients were in suppressive therapy with thyroid hormones. The basal TSH was normal in all the patients and less than 2 μ/ml in 20 patients. The TRH test was negative (no TSH response) in 27 patients and in all the cases with the basal TSH lower than 2 μU/ml.
Get full access to this article
View all access options for this article.
References
1.
AbeY., IchikawaY., MurakyT., ItoK., HommaM.: Thyrotropin (TSH) receptor and adenylate-cyclase activity in human thyroid tumors: absence of high affinity receptors and loss of TSH responsiveness in undifferentiated thyroid carcinoma.J. Clin. Endocrinol. Metab., 52: 23–28, 1981.
2.
BalmeH.W.: Metastatic carcinoma of the thyroid successfully treated with thyroxine.Lancet, 1: 812–813, 1954.
3.
BusnardoB., VangelistaR., GirelliM.E., BuiF., LazziC.: TSH levels and TSH response to TRH as a guide to the replacement treatment of patients with thyroid carcinoma.J. Clin. Endocrinol. Metab., 42: 901–906, 1976.
4.
ByarD.P., GreeS.B., DorP., WilliamsD.: A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C.group. Eur. J. Cancer, 15: 1033–1041, 1979.
CarayonP., Thomas-MorvanC., CastanasE., Tu-bianaM.: Human thyroid cancer: membrane thyrotropin binding and adenylate-cyclase activity.J. Clin. Endocrinol. Metab., 51: 915–920, 1980.
7.
CarcangiuM.L., ZampiG., CastagnoliA., RosaiJ.: Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy.Cancer, 55: 805–828, 1985.
8.
CrileG.Jr.: Endocrine dependency of papillary carcinomas of the thyroid.JAMA, 195: 101–104, 1966.
9.
CrileG.Jr.: Changing end results in patients with papillary carcinoma of the thyroid.Surg. Gynecol. Obstet., 3: 460–468, 1971.
10.
De CosseJ.J., BeierwaltersW.H., BrooksJ.R., ThomasC.G., WoolnerL.B.: Carcinoma of the thyroid.Arch. Surg., 110: 783–789, 1975.
11.
FranssilaK.O.: Prognosis in thyroid cancer.Cancer, 36: 1138–1146, 1975.
12.
FrazellE.L., FooteF.W.: Papillary cancer of the thyroid: a review of 25 years of experience.Cancer, 11: 895–922, 1958.
13.
GwinupG., EliasE.: Evidence for TSH auto-regulation of thyroid carcinoma.Am. J. Med. Sci., 287: 42–43, 1984.
14.
HoffmanD.P., SurksM.I., OppenheimerJ.H., WeitzmanE.D.: Response to thyrotropin-releasing: hormone: an objective criterion for the adequacy of thyrotropin suppression therapy.J. Clin. Endocrinol. Metab., 44: 892–901, 1977.
15.
KohlerP.O.: Deseases of the hypothalamus and anterior pituitary. In: Harrison's Principles of Internal Medicine.Ninth edition, pp. 1667–1684, McGraw-Hill Kogakusha, Tokyo, 1980.
16.
PupiA., CastagnoliA., MorottiA., La CavaG., MeldolesiU.: Prognostic value of 131-1 whole body scan in postsurgical therapy of differentiated thyroid cancer.Cancer, 52: 439–441, 1983.
